| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.
|
JAMA
|
2011
|
4.52
|
|
2
|
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.
|
JAMA
|
2012
|
3.91
|
|
3
|
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
|
Circulation
|
2006
|
3.69
|
|
4
|
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.
|
JAMA
|
2012
|
3.30
|
|
5
|
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Hypertension
|
2012
|
2.42
|
|
6
|
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.
|
Am Heart J
|
2009
|
2.29
|
|
7
|
Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines.
|
Hypertension
|
2009
|
1.92
|
|
8
|
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use.
|
Arch Intern Med
|
2010
|
1.64
|
|
9
|
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
|
Clin J Am Soc Nephrol
|
2012
|
1.62
|
|
10
|
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
1.59
|
|
11
|
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
|
Am Heart J
|
2007
|
1.33
|
|
12
|
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
|
J Clin Hypertens (Greenwich)
|
2011
|
1.04
|
|
13
|
Prior preterm or small-for-gestational-age birth related to maternal metabolic syndrome.
|
Obstet Gynecol
|
2011
|
0.96
|
|
14
|
Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines.
|
J Clin Hypertens (Greenwich)
|
2012
|
0.95
|
|
15
|
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Hypertension
|
2007
|
0.95
|
|
16
|
Adverse association between diabetic retinopathy and cardiac structure and function.
|
Am Heart J
|
2008
|
0.92
|
|
17
|
Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project.
|
Clin Trials
|
2009
|
0.86
|
|
18
|
Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
J Clin Hypertens (Greenwich)
|
2003
|
0.85
|
|
19
|
Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?
|
J Clin Hypertens (Greenwich)
|
2009
|
0.84
|
|
20
|
Prior preterm birth and maternal subclinical cardiovascular disease 4 to 12 years after pregnancy.
|
J Womens Health (Larchmt)
|
2013
|
0.80
|
|
21
|
CD4+ cell count and HIV load as predictors of size of anal warts over time in HIV-infected women.
|
J Infect Dis
|
2012
|
0.78
|
|
22
|
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
|
J Clin Hypertens (Greenwich)
|
2013
|
0.75
|
|
23
|
Continuous safety monitoring for randomized controlled clinical trials.
|
Contemp Clin Trials
|
2011
|
0.75
|
|
24
|
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerations.
|
Contemp Clin Trials
|
2011
|
0.75
|
|
25
|
Comparison of the global statistical test and composite outcome for secondary analyses of multiple coronary heart disease outcomes.
|
Prog Cardiovasc Dis
|
2012
|
0.75
|
|
26
|
Association between chronic kidney disease and cancer mortality: A report from the ALLHAT.
|
Clin Nephrol
|
2016
|
0.75
|
|
27
|
Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 2: Statistical considerations.
|
Contemp Clin Trials
|
2011
|
0.75
|
|
28
|
Two Decades of ICU Utilization and Hospital Outcomes in a Comprehensive Cancer Center.
|
Crit Care Med
|
2016
|
0.75
|
|
29
|
Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy.
|
Int J Gynecol Cancer
|
2016
|
0.75
|